Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo + Corticosteroids in Ambulatory DMD
Duchenne Muscular Dystrophy
Enrolment: 73 · Results not recorded
Loading the evidence…
Biologic · Connective tissue growth factor inhibitor (INHIBITOR)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Duchenne Muscular Dystrophy
Enrolment: 73 · Results not recorded
Duchenne Muscular Dystrophy
Enrolment: 98 · Results not recorded
Idiopathic Pulmonary Fibrosis
Enrolment: 372 · Results not recorded
Idiopathic Pulmonary Fibrosis
Enrolment: 393 · Results not recorded
COVID-19 Respiratory Infection · COVID-19 Pneumonia · Covid19
Enrolment: 42 · Results not recorded
Liver Fibrosis Due to Chronic Hepatitis B Infection
Enrolment: 114 · Results not recorded
Type 2 Diabetes Mellitus · Diabetic Nephropathy · Diabetic Kidney Disease
Enrolment: 46 · Results not recorded
Locally Advanced or Metastatic Pancreatic Cancer
Enrolment: 50 · Results not recorded
Idiopathic Pulmonary Fibrosis
Enrolment: 21 · Results not recorded
Pancreatic Cancer
Enrolment: 0 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Single 20 Gy thoracic irradiation causing radiation pneumonitis and pulmonary fibrosis
FG-3019 prevented approximately 50 to 80% or reversed approximately 50% of lung remodelling, improved lung function and general health, and rescued mice from lethal irradiation (p less than 0.01). Treatment begun 16 weeks after irradiation reversed established remodelling and restored lung function…
Extraction: extract · Supplied extraction confidence: 0.78. Machine-extracted fields require source verification.